lumacaftor

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:chemical_compound
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Orkambi
gptkbp:activities corrects CFTR protein folding
gptkbp:approves gptkb:FDA
gptkbp:can_be_used_with gptkb:ivacaftor
gptkbp:clinical_trial Phase 3
long-term treatment
TRAFFIC
TRANSPORT
gptkbp:contraindication severe liver impairment
gptkbp:developed_by gptkb:Vertex_Pharmaceuticals
gptkbp:education necessary for understanding treatment
gptkbp:effective_date gptkb:2015
gptkbp:excretion urine
https://www.w3.org/2000/01/rdf-schema#label lumacaftor
gptkbp:indication homozygous F508del mutation in CFTR gene
gptkbp:ingredients C24 H26 Cl F2 N3 O2 S
gptkbp:interacts_with with strong CY P3 A inducers
with strong CY P3 A inhibitors
gptkbp:is_atype_of R07 A X03
gptkbp:is_used_for gptkb:cystic_fibrosis
gptkbp:lifespan about 24 hours
gptkbp:manager oral
gptkbp:marketed_as gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Orkambi
gptkb:Native_American_tribe
gptkbp:pharmacokinetics metabolized by CY P3 A
gptkbp:population adults and children over 2 years
gptkbp:regulatory_compliance gptkb:Health_Canada
gptkb:European_Medicines_Agency
Australian Therapeutic Goods Administration
gptkbp:research_areas personalized medicine
drug delivery systems
genetic therapies
clinical outcomes in CF
gptkbp:research_focus gptkb:CFTR_modulators
gptkbp:safety_features generally well tolerated
gptkbp:side_effect fatigue
headache
nausea
diarrhea
rash
liver enzyme elevation
respiratory symptoms
gastrointestinal symptoms
gptkbp:targets gptkb:cystic_fibrosis
gptkbp:treatment improve quality of life
improve lung function
reduce pulmonary exacerbations
with ivacaftor
gptkbp:type_of 1005290-37-4
gptkbp:type_of_care important for treatment efficacy
gptkbp:weight 471.00 g/mol